Infectious Diseases in Obstetrics and Gynecology
Volume 2009 (2009), Article ID 105376, 7 pages
doi:10.1155/2009/105376
Clinical Study

Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes

Mark G. Martens,1 Kenneth H. Fife,2 Peter A. Leone,3 Lynn P. Dix,4 and Clare A. Brennan4

1Planned Parenthood of Arkansas and Eastern Oklahoma, Inc., 5780 S. Peoria Ave, Tulsa, OK 74105, USA
2Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
3Division of Infections Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
4GlaxoSmithKline, Research Triangle Park, NC 27709, USA

Received 26 March 2009; Accepted 17 June 2009

Academic Editor: Jane R. Schwebke

Copyright © 2009 Mark G. Martens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Smith and N. J. Robinson, “Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review,” Journal of Infectious Diseases, vol. 186, supplement 1, pp. S3–S28, 2002. View at Publisher · View at Google Scholar · View at PubMed
  2. L. Corey and H. H. Handsfield, “Genital herpes and public health: addressing a global problem,” Journal of the American Medical Association, vol. 283, no. 6, pp. 791–794, 2000.
  3. F. Xu, M. R. Sternberg, B. J. Kottiri, et al., “Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States,” Journal of the American Medical Association, vol. 296, no. 8, pp. 964–973, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. W. Cates Jr., “Estimates of the incidence and prevalence of sexually transmitted diseases in the United States,” Sexually Transmitted Diseases, vol. 26, supplement 4, pp. S2–S7, 1999.
  5. “Centers for Disease Control (CDC) and Prevention. Sexually Transmitted Diseases Treatment Guidelines,” Morbidity and Mortality Weekly Report, vol. 55, (RR:11), pp. 1–92, 2006.
  6. A. Langenberg, J. Benedetti, J. Jenkins, R. Ashley, C. Winter, and L. Corey, “Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic” herpes simplex virus type 2 infection,” Annals of Internal Medicine, vol. 110, no. 11, pp. 882–887, 1989.
  7. J. Benedetti, L. Corey, and R. Ashley, “Recurrence rates in genital herpes after symptomatic first-episode infection,” Annals of Internal Medicine, vol. 121, no. 11, pp. 847–854, 1994.
  8. A. Wald, J. Zeh, S. Selke, R. L. Ashley, and L. Corey, “Virologic characteristics of subclinical and symptomatic genital herpes infections,” The New England Journal of Medicine, vol. 333, no. 12, pp. 770–775, 1995. View at Publisher · View at Google Scholar
  9. A. Wald, L. Corey, R. Cone, A. Hobson, G. Davis, and J. Zeh, “Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment,” The Journal of Clinical Investigation, vol. 99, no. 5, pp. 1092–1097, 1997.
  10. J. K. Benedetti, J. Zeh, and L. Corey, “Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time,” Annals of Internal Medicine, vol. 131, no. 1, pp. 14–20, 1999.
  11. R. Gupta, A. Wald, E. Krantz, et al., “Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract,” Journal of Infectious Diseases, vol. 190, no. 8, pp. 1374–1381, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. L. Corey, A. Wald, R. Patel, et al., “Once-daily valacyclovir to reduce the risk of transmission of genital herpes,” The New England Journal of Medicine, vol. 350, no. 1, pp. 11–20, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. K. H. Fife, T. J. Warren, R. D. Ferrera, et al., “Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial,” Mayo Clinic Proceedings, vol. 81, no. 10, pp. 1321–1327, 2006.
  14. S. E. Barton, P. E. Munday, and R. J. Patel, “Asymptomatic shedding of herpes simplex virus from the genital tract: uncertainty and its consequences for patient management,” International Journal of STD and AIDS, vol. 7, no. 4, pp. 229–232, 1996. View at Publisher · View at Google Scholar
  15. R. Patel, F. M. Cowan, and S. E. Barton, “Advising patients with genital herpes,” British Medical Journal, vol. 314, no. 7074, pp. 85–86, 1997.
  16. F. Diaz-Mitoma, M. Ruben, S. Sacks, P. MacPherson, and G. Caissie, “Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes,” Journal of Clinical Microbiology, vol. 34, no. 3, pp. 657–663, 1996.
  17. S. E. Straus, J. F. Rooney, and C. Hallahan, “Acyclovir suppresses subclinical shedding of herpes simplex virus,” Annals of Internal Medicine, vol. 125, no. 9, pp. 776–777, 1996.
  18. H. H. Handsfield, T. Warren, M. Werner, and J. A. Phillips, “Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life,” Sexually Transmitted Diseases, vol. 34, no. 6, pp. 339–343, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. K. H. Fife, T. J. Warren, S. E. Justus, and C. K. Heitman, “An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients,” Sexually Transmitted Diseases, vol. 35, no. 7, pp. 668–673, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. A. J. Ryncarz, J. Goddard, A. Wald, M.-L. Huang, B. Roizman, and L. Corey, “Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples,” Journal of Clinical Microbiology, vol. 37, no. 6, pp. 1941–1947, 1999.
  21. G. G. Koch, “The use of non-parametric methods in the statistical analysis of the two-period change-over design,” Biometrics, vol. 28, no. 2, pp. 577–584, 1972.
  22. S. Senn, Crossover Trials in Clinical Trial Research, John Wiley & Sons, London, UK, 2nd edition, 2002.
  23. D. M. Koelle, J. Benedetti, A. Langenberg, and L. Corey, “Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes,” Annals of Internal Medicine, vol. 116, no. 6, pp. 433–437, 1992.